Drugs / Avapritinib
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | AYVAKIT | — | 2021-06-16 – 2023-05-22 | fda.gov ↗ |
| Approved · conditional | EU (EMA) | Ayvakyt | — | 2020-09-24 | europa.eu ↗ |
| Approved | US (FDA) | AYVAKIT | — | 2020-01-09 | fda.gov ↗ |
Trials 22 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03862885 Background | — | gastrointestinal stromal tumor | Blueprint Medicines Corporation | Approved for marketing | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avapritinib | “Avapritinib is a type 1 kinase inhibitor designed to potently and selectively inhibit oncogenic KIT/PDGFRA mutants by targeting the kinase active conformation.” PMID 36477870 ↗ Feb 202322“Drug: Avapritinib” NCT04116541 ↗ |
| Known as | 70C366 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4204794 ↗ |
| Known as | Ayvakit | ChEMBL registry synonym — accepted as the source's own label CHEMBL4204794 ↗ |
| Known as | Ayvakyt | ChEMBL registry synonym — accepted as the source's own label CHEMBL4204794 ↗ |
| Known as | BLU-285 | “This phase 1 study ( NCT02561988 ) evaluated avapritinib (BLU-285), a selective KIT D816V inhibitor, in patients with AdvSM.” PMID 34873347 ↗ Dec 20211“This record comprises the currently available Expanded Access Programs (EAP) for avapritinib (BLU-285):” NCT04714086 ↗ |
| Known as | C-366 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4204794 ↗ |
| Known as | X-720776 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4204794 ↗ |
| Action | Inhibit | “Avapritinib selectively and potently inhibits KIT- and PDGFRA-mutant kinases.” PMID 34343033 ↗ Aug 2021 |
| Modality | Small molecule | “a small molecular targeted agent (Avapritinib)” NCT07028073 ↗ |
| Route | Oral | “administered orally (PO)” NCT02561988 ↗ |
| Target | KIT | “Avapritinib selectively and potently inhibits KIT- and PDGFRA-mutant kinases.” PMID 34343033 ↗ Aug 2021 |
| Target | PDGFRA | “Avapritinib selectively and potently inhibits KIT- and PDGFRA-mutant kinases.” PMID 34343033 ↗ Aug 2021 |